Literature DB >> 22768790

Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.

Anna Perols1, Hadis Honarvar, Joanna Strand, Ramkumar Selvaraju, Anna Orlova, Amelie Eriksson Karlström, Vladimir Tolmachev.   

Abstract

Affibody molecules are a class of affinity proteins. Their small size (7 kDa) in combination with the high (subnanomolar) affinity for a number of cancer-associated molecular targets makes them suitable for molecular imaging. Earlier studies demonstrated that the selection of radionuclide and chelator may substantially influence the tumor-targeting properties of affibody molecules. Moreover, the placement of chelators for labeling of affibody molecules with (99m)Tc at different positions in affibody molecules influenced both blood clearance rate and uptake in healthy tissues. This introduces an opportunity to improve the contrast of affibody-mediated imaging. In this comparative study, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was conjugated to the synthetic affibody molecule Z(HER2:S1) at three different positions: DOTA-A1-Z(HER2:S1) (N-terminus), DOTA-K58-Z(HER2:S1) (C-terminus), and DOTA-K50-Z(HER2:S1) (middle of helix 3). The affinity for HER2 differed slightly among the variants and the K(D) values were determined to be 133 pM, 107 pM and 94 pM for DOTA-A1-Z(HER2:S1), DOTA-K50-Z(HER2:S1), and DOTA-K58-Z(HER2:S1), respectively. Z(HER2:S1)-K50-DOTA showed a slightly lower melting point (57 °C) compared to DOTA-A1-Z(HER2:S1) (64 °C) and DOTA-K58-Z(HER2:S1) (62 °C), but all variants showed good refolding properties after heat treatment. All conjugates were successfully labeled with (111)In resulting in a radiochemical yield of 99% with preserved binding capacity. In vitro specificity studies using SKOV-3 and LS174T cell lines showed that the binding of the radiolabeled compounds was HER2 receptor-mediated, which also was verified in vivo using BALB/C nu/nu mice with LS174T and Ramos lymphoma xenografts. The three conjugates all showed specific uptake in LS174T xenografts in nude mice, where DOTA-A1-Z(HER2:S1)and DOTA-K58-Z(HER2:S1) showed the highest uptake. Overall, DOTA-K58-Z(HER2:S1) provided the highest tumor-to-blood ratio, which is important for a high-contrast imaging. In conclusion, the positioning of the DOTA chelator influences the cellular processing and the biodistribution pattern of radiolabeled affibody molecules, creating preconditions for imaging optimization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22768790     DOI: 10.1021/bc3002369

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  15 in total

1.  Site-selective protein-modification chemistry for basic biology and drug development.

Authors:  Nikolaus Krall; Filipa P da Cruz; Omar Boutureira; Gonçalo J L Bernardes
Journal:  Nat Chem       Date:  2015-11-30       Impact factor: 24.427

Review 2.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

3.  Alternative Non-Antibody Protein Scaffolds for Molecular Imaging of Cancer.

Authors:  Lawrence A Stern; Brett A Case; Benjamin J Hackel
Journal:  Curr Opin Chem Eng       Date:  2013-11       Impact factor: 5.163

4.  PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.

Authors:  Shibo Qi; Susan Hoppmann; Yingding Xu; Zhen Cheng
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

5.  Metal based imaging probes of DO3A-Act-Met for LAT1 mediated methionine specific tumors: synthesis and preclinical evaluation.

Authors:  K Ganesh Kadiyala; Anupama Datta; Jyoti Tanwar; Anupriya Adhikari; B S Hemanth Kumar; Krishna Chuttani; Meganathan Thirumal; Anil K Mishra
Journal:  Pharm Res       Date:  2014-09-10       Impact factor: 4.200

6.  Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.

Authors:  Robert Goldstein; Jane Sosabowski; Maria Livanos; Julius Leyton; Kim Vigor; Gaurav Bhavsar; Gabriela Nagy-Davidescu; Mohammed Rashid; Enrique Miranda; Jenny Yeung; Berend Tolner; Andreas Plückthun; Stephen Mather; Tim Meyer; Kerry Chester
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-13       Impact factor: 9.236

7.  Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.

Authors:  Hadis Honarvar; Kristina Westerlund; Mohamed Altai; Mattias Sandström; Anna Orlova; Vladimir Tolmachev; Amelie Eriksson Karlström
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

8.  Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain.

Authors:  Yongsheng Liu; Anzhelika Vorobyeva; Tianqi Xu; Anna Orlova; Annika Loftenius; Theresa Bengtsson; Per Jonasson; Vladimir Tolmachev; Fredrik Y Frejd
Journal:  Pharmaceutics       Date:  2021-06-07       Impact factor: 6.321

9.  Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.

Authors:  Joanna Strand; Hadis Honarvar; Anna Perols; Anna Orlova; Ram Kumar Selvaraju; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

Review 10.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.

Authors:  Matthias D'Huyvetter; Catarina Xavier; Vicky Caveliers; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Expert Opin Drug Deliv       Date:  2014-07-18       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.